Ataprost (ONO 41483), an orally active analogue of Carboprostacyclin, demonstrates 2.6 times greater efficacy than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Furthermore, it has been shown to alleviate coronary spasm [1].